Combined CTLA-4/CD80 and PD-1/PD-L1 Checkpoint Interactions Predict Response to Anti-PD-1/PD-L1 Therapy in NSCLC
What This Study Shows
Building on the breakthrough PD-1/PD-L1 findings, this study shows that measuring a second immune checkpoint—CTLA-4/CD80—provides additional predictive power. When both checkpoints are actively engaged, patients show the best responses to immunotherapy.
Critically, neither biomarker predicted response to chemotherapy, confirming they are specific predictors of immunotherapy benefit—not just general prognostic markers.
Key Findings
"Double High" Survival
Patients with high interaction at BOTH checkpoints (PD-1/PD-L1 + CTLA-4/CD80) had median overall survival of 35 months—the best outcomes in the study.
Study Cohort
NSCLC patients treated with anti-PD-1/PD-L1 immunotherapy, with parallel assessment of both checkpoint pathways.
Combined Biomarker Power
The study stratified patients by both checkpoint interactions:
Specificity for Immunotherapy
A critical finding: these biomarkers specifically predict response to immune checkpoint inhibitors, not chemotherapy. In a chemotherapy-treated control group, neither PD-1/PD-L1 nor CTLA-4/CD80 interaction predicted outcomes.
This confirms the biomarkers are measuring the mechanism of action—immune checkpoint engagement—rather than being general tumor biology markers.
Clinical Implications
- 🎯 Multi-pathway profiling: Assessing both checkpoints provides a more complete picture of tumor immune evasion mechanisms.
- 💊 Combination therapy guidance: Patients with high CTLA-4/CD80 but low PD-1/PD-L1 might benefit from ipilimumab-based regimens.
- ✅ Mechanism confirmation: The chemotherapy non-prediction confirms biomarker specificity for ICI mechanisms.
Learn More
Abstract
The CTLA-4/CD80 pathway represents a distinct checkpoint axis regulating T-cell priming in lymphoid tissue. We hypothesized that quantitative assessment of both CTLA-4/CD80 and PD-1/PD-L1 interactions would improve predictive stratification for anti-PD-1/PD-L1 therapy. Using iFRET on the QF-Pro platform, we measured both checkpoint interactions in 67 NSCLC patients treated with anti-PD-1/PD-L1 monotherapy or combination therapy.
Methods
iFRET Assays: Sequential dual-checkpoint iFRET was performed on FFPE sections. PD-1/PD-L1 interaction was measured at the tumor-immune interface; CTLA-4/CD80 interaction was assessed in tumor-infiltrating lymphocyte (TIL) clusters.
Stratification: Patients were classified into four groups based on above/below median iFRET values for each checkpoint pathway.
Control Cohort: A separate cohort of 42 NSCLC patients treated with platinum-doublet chemotherapy served as a specificity control.
Key Findings
Double-High Median OS
Patients with high iFRET for both PD-1/PD-L1 AND CTLA-4/CD80 achieved 35-month median OS (95% CI: 28.1-41.9).
Double-Low Median OS
Double-low patients showed 8-month median OS, representing a 4.4-fold difference from double-high (P < 0.0001).
Specificity Control
Neither biomarker showed significant association with OS in chemotherapy-treated patients (P = 0.71 and P = 0.58), confirming ICI-specificity.
Biological Rationale
Complementary pathways: PD-1/PD-L1 primarily regulates T-cell effector function at the tumor site, while CTLA-4/CD80 modulates T-cell priming and regulatory T-cell (Treg) function. High engagement of both pathways indicates tumors employing multiple immune evasion mechanisms.
Response prediction: Paradoxically, high checkpoint engagement predicts better ICI response—tumors actively suppressing immunity via these checkpoints are vulnerable when those checkpoints are blocked.
Multivariate Analysis
Cox proportional hazards modeling including age, ECOG PS, stage, histology, and both iFRET biomarkers confirmed independent prognostic value:
- 📊 PD-1/PD-L1 iFRET: HR = 0.42 (95% CI: 0.26-0.68), P = 0.0003
- 📊 CTLA-4/CD80 iFRET: HR = 0.61 (95% CI: 0.39-0.95), P = 0.028
- 📊 Combined model C-statistic: 0.74 vs. 0.62 for PD-L1 TPS alone